

CLAIM AMENDMENTS

Please amend the claims as follows:

1-12. (Cancelled)

13. (Currently Amended) A method of production of stratified, differentiated mammalian urothelium in which urothelial cells, isolated from the mammalian body, are passaged through a first nutrient medium containing the components of serum and then redispersed before going on in being added to a like second medium containing components of serum to form said urothelium.

14. (Previously Presented) The method of claim 13 wherein the mammalian urothelium is human urothelium.

15. (Previously Presented) The method of claim 13 in which the serum is bovine serum.

16. (Previously Presented) The method of claim 15 in which the serum is adult bovine serum.

17. (Previously Presented) The method of claim 13 in which the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 1% and about 30% related to the concentration of said components in whole serum.

18. (Previously Presented) The method of claim 13 in which the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 3% and about 10% related to the concentration of said components in whole serum.

19. (Previously Presented) The method of claim 13 wherein the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 4% and about 6% related to the concentration of said components in whole serum.

20. (Previously Presented) The method of claim 13 wherein the nutrient medium is, or is a derivative of, MCDB-153 medium.

21. (Previously Presented) The method of claim 13 wherein the nutrient medium is KSFM (Keratinocyte Serum Free Medium).

22. (Currently Amended) The method of claim 13 wherein the nutrient medium is supplemented by one or more of Epidermal Growth Factor (EGF); Bovine Pituitary Extract (BPE); or Cholera Toxin (CT).

23. (Previously Presented) Urothelium produced by the method of claim 13.

24. (New) A method of production of stratified, differentiated mammalian urothelium, the method comprising:

culturing mammalian urothelial cells into a first cell culture medium substantially devoid of serum to form a primary culture of urothelial cells;

dispersing the urothelial cells of the primary culture into a second cell culture medium that includes serum;

culturing the urothelial cells in the second culture medium to form a secondary cell culture having aggregated urothelial cells;

dispersing the aggregated urothelial cells into a third cell culture medium that includes serum; and

culturing the urothelial cells in the third culture medium to form stratified, differentiated mammalian urothelium.

25. (New) A method as in claim 24, wherein the aggregated urothelial cells are at least partially confluent.

26. (New) A method as in claim 24, wherein the aggregated urothelial cells approach confluence.

27. (New) A method as in claim 24, wherein the secondary cell culture and/or urothelium is substantially devoid of a feeding layer of cells.

28. (New) A method as in claim 24, wherein the culturing of the urothelial cells in the second and/or third culture media is substantially devoid of growing the urothelial cells on 3T3 cells or with media incubated with 3T3 cells.

29. (New) A method as in claim 24, wherein the serum is at a concentration between about 1% and about 30% of the medium.

30. (New) A method as in claim 24, wherein the serum is at a concentration between about 4% and about 6% of the medium.

31. (New) A method as in claim 24, wherein the first, second, and/or third cell culture medium is one of MCDB-153 medium, KSFM (Keratinocyte Serum Free Medium), or a medium derived thereof.

32. (New) A method as in claim 24, wherein first, second, and/or third cell culture medium is supplemented by at least one of Epidermal Growth Factor (EGF), Bovine Pituitary Extract (BPE), or Cholera Toxin (CT).